The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Great find HelloSanDiego, from the article a great little section
Stephen Chapman, a respiratory medicine physician at the Wellcome Centre for Human Genetics in Oxford, who was not involved in the research, said the papers made an important contribution towards explaining why disease severity varies so dramatically between individuals. Of the auto-antibody finding, he said: “If this is true it is an astonishing result.”
It should guide diagnosis and treatment, since patients arriving at hospital and testing positive for auto-antibodies could undergo plasma exchange to remove those antibodies from their blood – potentially keeping them out of intensive care. Since the auto-antibodies spare one particular form of interferon – the beta form – these patients might also benefit from the experimental treatment inhaled interferon beta. (The last bit linked to the Guardian story on Six of the most promising treatments for Covid-19 so far which featured SNG)
https://www.washingtonpost.com/health/2020/09/22/fda-covid-vaccine-approval-standard/
FDA are concerned the lack of transparency re vaccines will result in low usage and uptick in anti vax sentiment. This news definitely bodes well for therapeutics and in particular SNG
Punit is a constant de-ramper best ignored/filtered.
GLA DYOR
The RNS on 8th Sept was clear in that Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients.
- SNG001 well tolerated in this older population with a significant co-morbidity (COPD)
- Strong interferon driven antiviral biomarker response
- Data support future progression of SNG001 for exacerbating COPD patients
- Positive data supportive of SNG001 COVID-19 programme
Only then did it say it was putting the COPD focus on hold temporarily to focus on utilising SNG001 as a treatment for COVID. This was temporary.
The value for using SNG001 for COPD is still huge.
Today's briefing to me was purely to prep the country for more bad news down the line. This is where we are now, this is where we'll be in mid Oct if nothing changes. It's back, it's doubling every 7 days but this time it's Autumn Winter and things could be a whole lot worse. Discussing positive things (like treatments) weren't part of the play. We got a bit on Vaccines but with a caviat that we may have something by the end of the year but only may, no guarantees.
From an SNG perspective, nothing changes. SNG didn't fit the narative for today so would never have been included anyway. We still have an offering that can save lives. The govt will need it sooner rather than later, if he doesn't then some other country will take it.
If RN is having multiple convos with multiple countries/pharma's etc, his biggest headache will be ramping production because you can't save lives unless you've got something to give to people.
Keep the faith folks, GLA and DYOR
Now, I'm sure I've missed a few stocks but you need to jog on, personally, I'm very happy with my return so far and AVCT haven't even hit their major SP growth point unlike a lot of the other shares.....
AVCT is a strong buy or strong hold Simple As
You're so full of crap Always Whining, sick of it, quick little check, Avacta are 662% up since 1st Feb and from what I can see
Stock Name Stock Code SP 3rd Feb 2020 SP 16th Sept Difference % Increase
Synairgen PLC SNG £0.1185 £1.8500 £1.7315 1461.18%
Novacyt SA NCYT £0.4850 £3.7000 £3.2150 662.89%
Avacta Group PLC AVCT £0.2425 £1.7700 £1.5275 629.90%
Genedrive GDR £0.2100 £1.3000 £1.0900 519.05%
Omega Diagnostics Group Plc ODX £0.1477 £0.8800 £0.7323 495.80%
Hemogenyx Pharmaceuticals PLC HEMO £0.0188 £0.1040 £0.0852 453.19%
Tiziana Life Sciences PLC TILS £0.4000 £1.4700 £1.0700 267.50%
Braveheart Inv BRH £0.1000 £0.2200 £0.1200 120.00%
Beximco Pharma BXP £0.4200 £0.6250 £0.2050 48.81%